# A Multiple Dose of HL237 in Healthy Male Subject

> **NCT03896594** · PHASE1 · UNKNOWN · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** HL237
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03896594
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-24
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03896594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03896594, "A Multiple Dose of HL237 in Healthy Male Subject". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03896594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*